An early demonstration of the utility of CRISPR-Cas9 genome editing in cardiomyopathy modeling involved the correction of a pathogenic SCN5A (OMIM: 600163) mutation in patient-derived iPSC-CMs, thereby establishing the causative role of SCN5A in arrhythmogenic right ventricular cardiomyopathy (ARVC) [137]. This evidence concerns the gene SCN5A and Arrhythmogenic right ventricular dysplasia.